Zdrowie i gospodarka · 11/10/2022
FDA Director Proposes to Refuse Approval of Vanda's HETLIOZ Supplement
The FDA Director is proposing to reject Vanda Pharmaceuticals' supplemental new drug application for HETLIOZ (tasimelteon) capsules due to concerns, and offers Vanda the chance to request a hearing on the matter.